

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S):	Keene <i>et al.</i>	ART UNIT:	1633
SERIAL NUMBER:	10/629,453	CONFIRMATION NO.:	5725
FILING DATE:	July 29, 2003	EXAMINER:	MARVICH, Maria
TITLE:	METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**FILED ELECTRONICALLY**

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

In accordance with 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner a U.S. patent and co-pending applications that claim the benefits of at least one same prior-filed application as does the instant application. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached SB/08 form. Copies of the currently pending claims in the co-pending applications are attached.


This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action or a Notice of Allowance. Under 37 C.F.R. § 1.97(c), please charge a fee of \$180.00 as specified by § 1.17(p) and any other required fees to Deposit Account 50-1283.

Applicants reserve the right to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Dated: November 6, 2007

Respectfully submitted,  
COOLEY GODWARD KRONISH LLP

By:

  
Konstantin M. Linnik  
Reg. No. 56,309  
Tel.: (617) 937-2340  
Email: [klinnik@cooley.com](mailto:klinnik@cooley.com)